Exploring the interdependencies of research funders in the UK

Investment in medical research is vital to the continuing improvement of the UK's health and wealth. It is through research that we expand our understanding of disease and develop new treatments for patients. Medical research charities currently contribute over £1 billion annually to medical research in the UK, of which over £350 million is provided by Cancer Research UK. Many charities, including Cancer Research UK, receive no government funding for their research activity. Cancer Research UK is engaged in a programme of work in order to better understand the medical research funding environment and demonstrate the importance of sustained investment. A key part of that is the Office of Health Economics‟ (OHE) 2011 report “Exploring the interdependency between public and charitable medical research”. This study found that there are substantial benefits, both financial and qualitative, from the existence of a variety of funders and that reductions in the level of government financial support for medical research are likely to have broader negative effects. This contributed to other evidence which found that the activities and funding of the charity, public and private sectors respectively are complementary, i.e. mutually reinforcing, rather than duplicative or merely substituting for one another. “Exploring the interdependencies of research funders in the UK” by the Office of Health Economics (OHE) and SPRU: Science and Technology Policy Research at the University of Sussex, represents a continued effort to build the evidence base around the funding of medical research. This report uncovers the extent to which funders of cancer research are interdependent, nationally and internationally. Key figures show that two thirds of publications acknowledging external support have relied on multiple funders, while just under half benefited from overseas funding, and almost a fifth are also supported by industry. In addition the analysis shows that the general public would not want tax funding of cancer research to be reduced, but would not donate enough to charities to compensate for any such reduction

Eccrine spiradenoma: an uncommon breast tumour

Eccrine spiradenoma is a benign tumour of the sweat gland. Eccrine glands can be found almost everywhere but are mostly concentrated on the palms, soles and the axillae. Lesions involving the breast are rare. We present a case of a 13-years-old Malay girl with eccrine spiradenoma of the breast. The clinical presentation and histological features are being described

Ultrasound Spectrum of Papillary Breast Neoplasms

Papillary breast neoplasms show a wide spectrum of pathologic changes, and the hallmark of these tumors is the presence of a fibrovascular core. Histologically, papillary breast neoplasms can be broadly divided into benign papillomas, atypical papillomas, and malignant papillary lesions. The papillary breast neoplasms have been described as having a varied appearance, but review of the imaging spectrum is limited. The purpose of this article is to review the characteristic sonographic features of the broad spectrum of papillary breast neoplasms from benign papillomas to malignant papillary lesionsope

Text Mining Of Variant-Genotype-Phenotype Associations From Biomedical Literature

In spite of the efforts in developing and maintaining accurate variant databases, a large number of disease-associated variants are still hidden in the biomedical literature. Curation of the biomedical literature in an effort to extract this information is a challenging task due to i) the complexity of natural language processing, ii) inconsistent use of standard recommendations for variant description, and iii) the lack of clarity and consistency in describing the variant-genotype-phenotype associations in the biomedical literature. In this article, we employ text mining and word cloud analysis techniques to address these challenges. The proposed framework extracts the variant-gene-disease associations from the full-length biomedical literature and designs an evidence-based variant-driven gene panel for a given condition. We validate the identified genes by showing their diagnostic abilities to predict the patients’ clinical outcomes on several independent validation cohorts. As representative examples, we present our results for acute myeloid leukemia (AML), breast cancer, and prostate cancer. We compare these panels with other variant-driven gene panels obtained from Clinvar, Mastermind, and others from literature, as well as with a panel identified with a classical differentially expressed genes (DEGs) approach. The results show that the panels obtained by the proposed framework yield better results than the other gene panels currently available in the literature

INFLAMMATORY BREAST NEOPLASMS: A SYSTEMATIC REVIEW

Overview: Inflammatory Breast Cancer (IBC) is a rare and very aggressive type of cancer that tends to develop at a younger age, compared with other subtypes of breast cancer. Because a distinct lump may not be noticeable, correct diagnosis takes longer and, therefore, successful treatment may hinder a patient’s prognostics. This study aims to conduct a systematic review of research articles on IBC. Methods: This is a systematic review of studies in the PubMed database to April 2013, which fit the eligibility criterion of “Inflammatory Breast Neoplasms” (MeSH Terms), filtered by Languages (English OR Portuguese OR Spanish). Findings: Of the 119studies identified, 25 complied with the eligibility criterion for the disease, diagnostics, treatment and prognostics. Final Considerations :Despite methodological differences, findings evidence that although IBC presents particular features (lower survival rate and worse prognostics than most types of breast cancer), very few studies examine its epidemiology and specific risk factors in depth and use any other therapeutic approaches than those commonly used for other breast cancer subtypes. Therefore, further investigation of the disease’s aggressiveness is still necessary

Overdiagnosis due to screening mammography for women aged 40 years and over

This is a protocol for a Cochrane Review. The objective was to assess the effect of screening mammography for breast cancer on overdiagnosis in women aged 40 years and older at average risk of breast cancer